Dr. Martens (LON:DOCS) Receives Buy Rating from Berenberg Bank

Dr. Martens (LON:DOCS)‘s stock had its “buy” rating reiterated by research analysts at Berenberg Bank in a note issued to investors on Tuesday, MarketBeat.com reports.

Separately, Peel Hunt reiterated a “buy” rating on shares of Dr. Martens in a research report on Thursday, November 20th. Two equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, Dr. Martens has a consensus rating of “Moderate Buy” and an average target price of GBX 6,000.

Dr. Martens Stock Performance

Shares of DOCS traded down GBX 9.50 on Tuesday, reaching GBX 66.15. The company’s stock had a trading volume of 5,113,644 shares, compared to its average volume of 1,825,940. The stock’s 50 day simple moving average is GBX 76.53 and its two-hundred day simple moving average is GBX 83.47. The company has a debt-to-equity ratio of 127.27, a current ratio of 2.85 and a quick ratio of 1.13. The stock has a market capitalization of £639.38 million, a P/E ratio of 38.91, a PEG ratio of 6.40 and a beta of 0.11. Dr. Martens has a 12-month low of GBX 43.02 and a 12-month high of GBX 100.87.

Dr. Martens (LON:DOCS) last announced its earnings results on Thursday, November 20th. The company reported GBX (0.90) EPS for the quarter. Dr. Martens had a net margin of 7.89% and a return on equity of 18.91%. Research analysts forecast that Dr. Martens will post 2.5809394 earnings per share for the current fiscal year.

Insider Activity at Dr. Martens

In other Dr. Martens news, insider Robert Hanson purchased 96,000 shares of the company’s stock in a transaction on Friday, December 5th. The stock was acquired at an average cost of GBX 79 per share, for a total transaction of £75,840. Insiders bought 97,130 shares of company stock valued at $7,673,816 in the last quarter. 2.79% of the stock is owned by insiders.

Key Stories Impacting Dr. Martens

Here are the key news stories impacting Dr. Martens this week:

• Positive Sentiment: Scaling back discounting should support gross margins and average selling prices, which can boost profitability if volumes don’t fall materially.
• Neutral Sentiment: The strategy signals a shift toward protecting brand value and margins rather than chasing revenue via promotions; outcome depends on consumer response and inventory execution.
• Negative Sentiment: The company guided to flat revenue for 2026, raising concerns about growth and prompting investor selling amid already-high leverage and a premium valuation. Dr Martens projects flat 2026 revenue as it scales back discounts

About Dr. Martens

Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history. It operates in over
60 countries and employs over 3,650 people worldwide. Its operations are split across both Direct-to-Consumer and
wholesale channels, and in addition to its world-renowned “1460” boot its product segments span shoes including the
1461 shoe and Adrian loafer, sandals including the Zebzag mule, Kids ranges, as well as a growing line of bags and
accessories.

The Company successfully listed on the main market of the London Stock Exchange on 29 January 2021 (DOCS.L) and
is a constituent of the FTSE 250 index.